Laura S. Kaiser

Jan 7, 2025 | openlegalblogarchive.org | Laura S. Kaiser

We’re thrilled to welcome Jennifer Glass to OG+S! Jenn brings over 15 years of experience in intellectual property, specializing in patent prosecution, as well as patent and trademark docketing. She holds a Bachelor of Science degree in Business Management from Cornerstone University. Jenn’s career spans a variety of industries within the legal field, including automotive and pharmaceutical, and she has worked in environments ranging from small firms to in-house positions with large corporations.

Jun 28, 2024 | inbusinessphx.com | Laura S. Kaiser |Benjamin Little

Corporate giving offers businesses a multitude of benefits, including creating a positive public image that can help attract customers, employees and investors while also increasing employee engagement and improving the company’s financial performance. Yet, some companies are unsure of the process to create a company-wide program and find themselves navigating several one-off requests throughout the year.

Mar 26, 2024 | lexblog.com | Laura S. Kaiser

I feel gratitude commemorating two enriching years at Ogden Glazer + Schafer (“OG+S”) as a Paralegal in the Intellectual Property practice. As I reflect on this milestone, I am struck by the journey, the career shift and finding myself in an environment that fosters growth, champions values of DEI, continual learning, and collaboration.

Mar 19, 2024 | chausa.org | Laura S. Kaiser

This past year, CHA introduced a new vision statement: We Will Empower Bold Change to Elevate Human Flourishing. It's an aspirational call to each of us in the Catholic health ministry. With just nine words, CHA's vision statement makes it clear that the health systems of tomorrow must be innovative and courageous, while embracing a mandate to further extend ourselves into all aspects of human flourishing.

Mar 13, 2024 | nature.com | Julie George |Lukas Maas |Nima Abedpour |Laura S. Kaiser |Andreas Scheel |Martin Hellmich | +11 more

AbstractThe evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown1,2,3. Here we determined tumour phylogenies at diagnosis and throughout chemotherapy and immunotherapy by multiregion sequencing of 160 tumours from 65 patients.